NASDAQ
02.11.26 | 21:59
6,710 US-Dollar
-0,30 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Profound Medical expands U.S. sales network through Cook Medical partnership | 1 | Seeking Alpha | ||
| PROFOUND MEDICAL Aktie jetzt für 0€ handeln | |||||
| Fr | Profound Medical Corp (2): Profound Medical signs Cook Medical as U.S. distributor | 1 | Stockwatch | ||
| Fr | Profound Medical schließt US-Vertriebsabkommen mit Cook Medical | 1 | Investing.com Deutsch | ||
| Fr | Profound Medical signs distribution deal with Cook Medical | 3 | Investing.com | ||
| Fr | Profound Medical Corp.: Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO Sales Channels and Drive Recurring Revenue Growth | 2 | GlobeNewswire (USA) | ||
| 22.10. | Profound Medical Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.10. | Profound Medical Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| 09.10. | Profound Medical Corp (2): Profound Medical, Telix sign prostate care deal | 4 | Stockwatch | ||
| 09.10. | Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care | 414 | AFX News | CANBERA (dpa-AFX) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the... ► Artikel lesen | |
| 09.10. | Profound Medical und Telix vereinbaren Bildungskooperation für Ärzte | 5 | Investing.com Deutsch | ||
| 09.10. | Profound Medical Corp.: Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care | 280 | GlobeNewswire (Europe) | Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO- Agreement provides... ► Artikel lesen | |
| 08.10. | Profound Medical: Raymond James bestätigt "Strong Buy" und sieht deutliches Kurspotenzial | - | Investing.com Deutsch | ||
| 08.10. | Raymond James reiterates Strong Buy on Profound Medical stock, $11 target | 1 | Investing.com | ||
| 08.10. | Profound Medical Corp (2): Profound Medical releases preliminary Q3 results | 1 | Stockwatch | ||
| 07.10. | Profound Medical-Aktie schießt nach angehobener Umsatzprognose um 20 % in die Höhe | 1 | Investing.com Deutsch | ||
| 07.10. | Profound Medical: Aktie schießt nach überraschend starker Umsatzprognose in die Höhe | - | Investing.com Deutsch | ||
| 07.10. | Profound Medical Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Profound Medical expects Q3 revenue could top estimates by 47% | 1 | Seeking Alpha | ||
| 07.10. | Profound Medical erwartet Umsatzsprung von bis zu 89 % im dritten Quartal | 2 | Investing.com Deutsch | ||
| 07.10. | Profound Medical anticipates Q3 revenue up to 89% year-over-year | 1 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,706 | -0,13 % | Piper Sandler raises Teladoc stock price target on BetterHelp growth | ||
| SERNOVA BIOTHERAPEUTICS | 0,068 | +21,15 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 1,420 | 0,00 % | Cerenome completes enrollment in glioblastoma drug trial | ||
| ATOSSA THERAPEUTICS | 2,040 | +0,99 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 17,000 | +1,80 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,353 | -0,03 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 11,630 | -7,18 % | Quidel Q3 2026 Earnings Preview | ||
| VERU | 2,160 | 0,00 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 6,040 | -1,31 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 3,840 | -0,52 % | Clover Health im Aufwind: Needham startet Coverage mit "Buy" und Kursziel von 6 Dollar | ||
| SENSEONICS | 8,000 | -0,62 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| NANO-X IMAGING | 0,302 | +0,03 % | NANO-X IMAGING LTD: TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI's AVC Solution | ||
| TEMPEST THERAPEUTICS | 0,472 | +0,06 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| IMUNON | 0,790 | 0,00 % | Imunon, Inc. - S-1, General form for registration of securities |
Das Unternehmen PROFOUND MEDICAL CORP kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,30 % bei einem Aktienkurs von 6,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFOUND MEDICAL CORP finden Sie auf Wallstreet Online.